All In Biotech

Drug Trial Radar · NCT02041299

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias

Last checked: Nov 20, 2026Latest source record: Aug 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

230

Actual

Start

Apr 17, 2014

Primary completion

Apr 20, 2019

Study completion Jun 18, 2019

Sponsor

Lead sponsor
ApoPharmaIndustry
Sponsor type
Industry
First posted
Jan 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Conditions

  • Iron Overload
  • Sickle Cell Disease
  • Other Anemias

Interventions

  • DeferiproneDrug

  • DeferoxamineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Liver Iron Concentration (LIC)Time frame: Change from baseline to Week 52

Locations

33 sites in 8 countries. Site status is shown where the registry gives one.

  • Children's Hospital Oakland

    Oakland, California

  • University of Illinois at Chicago

    Chicago, Illinois

  • Children's Hospital

    New Orleans, Louisiana

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Children's Hospital of Michigan

    Detroit, Michigan

  • The Children's Hospital of Philadephia

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Centro Infantil Boldrini

    Campinas, Brazil

  • Hospital de Clínicas de Porto Alegre-HCPA,

    Rio Branco, Brazil

  • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO

    Rio de Janeiro, Brazil

  • Casa de Saúde Santa Marcelina

    São Paulo, Brazil

  • Universidade Federal de São Paulo

    São Paulo, Brazil

  • Hospital for Sick Kids

    Toronto, Ontario, Canada

  • Mansoura University Children's Hospital

    Al Mansurah, Egypt

  • Alexandria University

    Alexandria, Egypt

  • Zagazig University

    Alexandria, Egypt

  • Ains Shams University

    Cairo, Egypt

  • Cairo University

    Cairo, Egypt

  • Pediatric Hospital of Cairo University

    Cairo, Egypt

  • Asser Central Hospital

    Abhā, Saudi Arabia

  • King Khalid University Hospital

    Riyadh, Saudi Arabia

  • King Abdulaziz University Hospital

    Jeddah, Western Region, Saudi Arabia

  • Farhat Hached Hospital, Hematology Department

    Sousse, Tunisia

  • Principal Military Hospital of Instruction of Tunis

    Tunis, Tunisia

  • National Center for Bone Marrow Transplantation

    Tunis, Bad Saadoun, Tunisia

  • Cukurova University

    Adana, Turkey (Türkiye)

  • Hacettepe University

    Ankara, Turkey (Türkiye)

  • Istanbul University

    Istanbul, Turkey (Türkiye)

  • Hammersmith Hospital

    London, United Kingdom

  • Barts and The London

    London, United Kingdom

  • Evelina Children's Hospital

    London, United Kingdom

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.